ConcertAI Provides Intelligent Automation of ASCO ® Guidelines into its Generative and Agentic AI Precision Suite™ and CancerLinQ ® SmartLinQ™ Solutions
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences, today announced the integration of the American Society of Clinical Oncology® (ASCO®) Guidelines through the CARAai platform for its Precision Suite and CancerLinQ® SmartLinQ solutions™. Now, the power of the Precision Suite's low-latency and high-recency data can be used by biopharma researchers to assess Guideline-concordant care and outcomes at any point in time or reviewing changes over time. Members of the CancerLinQ® network using SmartLinQ solutions will now have ASCO Guideline-concordant recommendations for their individual patients as an augmentation of their assessment of treatment options. This published information will be integrated with other SmartLinQ features that can help oncologists consider a complete set of treatment options for optimized patient outcomes.
In December of 2023, ASCO and ConcertAI announced the acquisition of CancerLinQ and ongoing network operations as a ConcertAI initiative. Over the last year and a half, ConcertAI has advanced the SmartLinQ application for QOPI® applications as well as advanced notifications of potentially beneficial diagnostics and newly approved therapeutics for a provider's patients. SmartLinQ works directly within the workflows of Epic and other EMRs. ASCO Guidelines will be augmenting the SmartLinQ solution by June 15th as part of the company's effort to assure that all network practices have that informational resource.
On May 30 th, ConcertAI announced its oncology Precision Suite™ of generative and agentic AI solutions for advancing analytics and inferences, and for clinical trial design and optimization. The ASCO Guidelines will be available within these solutions by June 30 th for assessment of Guideline-concordant care across the widest array of settings, and to inform the design of clinical trial controls according to published clinical recommendations.
'Through CancerLinQ, ConcertAI has an almost decade-long history of collaborating with ASCO,' said Jeff Elton, Ph.D., Vice Chairman of ConcertAI. 'This license of ASCO Guidelines represents a new opportunity to harness the latest generative and agentic AI technologies to promote high-quality cancer care, evidence generation, and advanced care insights.'
The CancerLinQ SmartLinQ deployment of these guidelines will be available to demonstrate at the 2025 ASCO Annual Meeting in Chicago.
About ConcertAI:
ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, Massachusetts, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
20 minutes ago
- Business Wire
Triple-I: US Personal Auto Insurance Industry Generates Profitable Underwriting Result but Faces Headwinds Due to Legal System Abuse, Regulatory Environment
MALVERN, Pa.--(BUSINESS WIRE)--The United States personal auto insurance industry achieved its strongest underwriting performance in the post-pandemic era, recording a net combined ratio of 95.3 in 2024, but continues to face headwinds due to escalating legal system abuse and a challenging regulatory environment, according to a new Issues Brief published today by the Insurance Information Institute (Triple-I). "The growing impacts of legal system abuse, driven by the exploitive tactics of billboard attorneys, combined with an increasingly complex regulatory environment, will continue to put pressure on the market." 'While the improved 2024 underwriting performance is encouraging, we remain focused on several challenges facing the personal auto insurance industry,' said Triple-I CEO Sean Kevelighan. 'The growing impacts of legal system abuse, driven by the exploitive tactics of billboard attorneys, combined with an increasingly complex regulatory environment, will continue to put pressure on the market. It's essential for auto insurers to continue managing these evolving risks effectively to sustain profitable growth.' Key Performance Highlights Triple-I's Issues Brief showed the personal auto insurance sector's improvement across multiple metrics in 2024: Premium Growth: The industry maintained robust growth momentum with a net written premium increase of 12.8% in 2024, following 14.4% growth in 2023. This marks two consecutive years of double-digit premium growth, outpacing the broader U.S. property/casualty (P/C) industry for the second consecutive year. Loss Performance: Direct incurred loss ratios improved dramatically, falling 21.7 percentage points from a peak of 86% in Q4 2022 to 64% by the end of 2024. This substantial improvement reflects the industry's successful efforts to align pricing with risk and implement effective loss control measures. Historical Context: The personal auto line has outperformed the net combined ratio of the overall U.S. P/C industry in 10 of the past 20 years since 2005. Ongoing Challenges and Emerging Risks Despite 2024's improved financial performance, the industry continues to face significant headwinds which could impact future results: Legal System Abuse: Increased billboard attorney involvement in claims and larger jury awards drove auto liability losses and defense and cost containment expenses up by a range of $76.3 billion to $81.3 billion from 2014 to 2023, according to a 2024 Triple-I/Casualty Actuarial Society study. Regulatory Environment: State regulatory processes have become increasingly challenging, with approval timeframes for rate filings growing 40% longer from 2010 to 2023. Additionally, the percentage of filings receiving less rate impact than requested by carriers has increased by 10 percentage points, potentially limiting market availability and competitive pricing. Frequency vs. Severity Trends: While claim frequency remains below pre-pandemic levels, severity continues to rise year-over-year, with pure premium trends increasing cumulatively by 25.0 points from 2019 to 2024. About the Insurance Information Institute (Triple-I) Since 1960, the Insurance Information Institute (Triple-I) has been the trusted voice of risk and insurance, delivering unique, data-driven insights to educate, elevate and connect consumers, industry professionals, policymakers and the media. An affiliate of The Institutes, Triple-I represents a diverse membership accounting for nearly 50% of all U.S. property/casualty premiums written. Our members include mutual and stock companies, personal and commercial lines, primary insurers and reinsurers – serving regional, national and global markets. About The Institutes The Institutes® are a not-for-profit comprised of diverse affiliates that educate, elevate, and connect people in the essential disciplines of risk management and insurance. Through products and services offered by The Institutes and nearly 20 affiliated business units, people and organizations are empowered to help those in need with a focus on understanding, predicting, and preventing losses to create a more resilient world. The Institutes is a registered trademark of The Institutes. All rights reserved.
Business Wire
21 minutes ago
- Business Wire
Specialities Inc. Introducing All Natural Bellentani Products
MILLINGTON, N.J.--(BUSINESS WIRE)-- Specialities, Inc. is thrilled to announce the arrival of the All-Natural line of Bellentani cured meat products, a premium Italian delicacy crafted with tradition and authenticity. Beginning July 2025, these exceptional items will be available to consumers nationwide, offering an unparalleled taste experience at an affordable retail price of $6.99 for a 3-oz package (price may vary by variety and location). Our Handcrafted Prosciutto is made with simple ingredients -- Bellentani Prosciutto is minimally processed, free from artificial ingredients, and delivers the rich, savory flavor that has made Italian prosciutto a beloved staple. Produced by Bellentani, a family-owned Company, a heritage brand dating back to 1821 in Modena, Italy, this prosciutto represents centuries of expertise and a commitment to excellence. We are proud to introduce this all-natural prosciutto that stays true to traditional Italian methods, ensuring the highest quality and purity in every slice. Whether enjoyed on a charcuterie board, layered in a sandwich, or paired with fresh fruit and cheese, All Natural Bellentani Prosciutto delivers an unmatched flavor experience for every occasion. Exclusively distributed by Specialities, Inc., All Natural Bellentani Prosciutto has the highest standards of safety and quality. To learn more about this exciting launch, visit or contact Specialities, Inc. at 1-908-647-6485. About Specialities, Inc. Based in Millington, NJ, Specialities, Inc. is a trusted distributor dedicated to bringing high-quality, authentic food products to consumers. With a focus on excellence and tradition, the company continues to deliver premium selections from renowned brands worldwide. Please join us on June 29 – July 1st, 2025, at the Summer Fancy Food Show in the JAVITS CENTER, NYC, to learn more about this and other innovative products.
Business Wire
21 minutes ago
- Business Wire
Specialities Inc. Partnership with Fromagerie Milleret
MILLINGTON, N.J.--(BUSINESS WIRE)--Specialities ®, Inc. is thrilled to announce our new partnership with Fromagerie Milleret of France. Founded in 1921 in Franche-Comté by Henri Milleret, the cheese factory continues to be family-owned and has been dedicated to cheese production for three generations. One of the standout features of Fromagerie Milleret is its commitment to quality milk. All the milk used in their cheeses is sourced from local farms within an average radius of 40 km from the dairy and is processed within 48 hours of collection. The predominant Montbéliarde breed of cows, recognized for their distinctive white coats with brown spots, contributes to the exceptional quality of their milk. Fromagerie Milleret specializes in fine cheeses, particularly their signature tender, soft-ripened cheese made with summer truffles from Italy. Their creamy Brie cheese, which is free from colors, preservatives, or additives, exemplifies the excellence of cheese produced by Fromagerie Milleret. With Milleret Fromagerie as a valued partner, Specialities, Inc. will continue to provide U.S. consumers with wonderful opportunities to discover new and exciting products. Founded in 1991, Specialities, Inc. is a respected importer, distributor, and category builder of specialty, value-added food products for the U.S. deli and specialty markets, as well as select quality-driven food service distributors. Our best-in-class products are sourced from both domestic and international origins. Please join us on June 28 – July 1st, 2025, at the Summer Fancy Food Show in the JAVITS CENTER, NYC, to learn more about this and other innovative products.
